Table of Contents The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of 12.8% since its launch. Return for 2023 was 36.6% , 2022 was -8% and 2021 was 19.1% . NAV as on 26 Jul 24 ₹28.5251 ↑ 0.52 (1.85 %) Net Assets (AUM) as on 30 Jun 2024 ₹949 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio 1.41 Expense Ratio 2.13 % Sharpe Ratio 2.077 Information Ratio 0.63 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 26 Jul 24 Duration Returns 1 Month 7.2% 3 Month 11.8% 6 Month 19% 1 Year 45.9% 3 Year 16.3% 5 Year 25.8% 10 Year 15 Year Since launch 12.8% Historical Annual Returns
Year Returns 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% 2015 Growth of 10k Over Years
Date Value 30 Jun 19 ₹10,000 30 Jun 20 ₹12,893 30 Jun 21 ₹19,859 30 Jun 22 ₹17,776 30 Jun 23 ₹21,106 30 Jun 24 ₹30,261 
Asset Allocation
Asset Class Value Cash 3.5% Equity 96.5% 
Sector Allocation
Sector Value Health Care 93.62% Basic Materials 2.17% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMADrug Manufacturers - Specialty & Generic 13% ₹122 Cr 804,300 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMADrug Manufacturers - Specialty & Generic 9% ₹89 Cr 741,000 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | LUPINDrug Manufacturers - Specialty & Generic 9% ₹83 Cr 510,240 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDYDrug Manufacturers - Specialty & Generic 7% ₹69 Cr 107,643 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | CIPLADrug Manufacturers - General 6% ₹61 Cr 415,000 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Dec 22 | ZYDUSLIFEDrug Manufacturers - Specialty & Generic 5% ₹51 Cr 471,287 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 5% ₹48 Cr 104,965 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | FORTISMedical Care Facilities 4% ₹41 Cr 855,100 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEMDrug Manufacturers - Specialty & Generic 4% ₹38 Cr 75,249 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSPMedical Care Facilities 4% ₹36 Cr 58,903
Talk to our investment specialistFund Managers
Name Since Tenure Meeta Shetty 9 Mar 21 3.31 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
Computer Age Management Services Ltd Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells LLP 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹28.5251
↑ 0.52 19 % 45.87 % 16.25 % 25.83 % TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹28.5251
↑ 0.52 19 % 45.87 % 16.25 % 25.83 % TATA India Pharma & Healthcare Fund
Growth ₹28.5251
↑ 0.52 19 % 45.87 % 16.25 % 25.83 % Data as on 26 Jul 24
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2024 Shepard Technologies Private Limited. All Rights Reserved